Trial Profile

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Diphenhydramine; Methylprednisolone; Paracetamol; Tacrolimus
Indications Membranous glomerulonephritis
Focus Registrational; Therapeutic Use
Acronyms MAJESTY
Sponsors Roche

Most Recent Events

15 Jul 2026 According to Roche media release, the results from the trial were published in the New England Journal of Medicine (NEJM).
15 Jul 2026 Results presented in the Roche media release.
15 Jul 2026 According to Roche media release, the data from the trial were presented at the 63rd European Renal Association (ERA) Congress in June 2026 as a late-breaking oral presentation.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com